3SOF

Profile :  


ATS Medical Inc.
3905 Annapolis Lane N
Suite 105
Minneapolis, MN 55447
United States - Map
Phone: 763-553-7736
Fax: 763-553-1492
Web Site: http://www.atsmedical.com

DETAILS  
Index Membership: N/A
Sector: Healthcare
Industry: Medical Appliances & Equipment
Full Time Employees: 254


BUSINESS SUMMARY  
ATS Medical, Inc. engages in the development, manufacture, and marketing of medical devices primarily used in cardiac surgery. It offers ATS Open Pivot Heart Valve, a mechanical heart valve, which is used to treat heart valve disease caused by the natural aging process, rheumatic heart disease, prosthetic valve failure, and congenital defects. The company also markets surgical cryotherapy products for the ablation of cardiac arrhythmias; RTI - CV processed cardiovascular allograft tissues; cardiac surgical products, including annuloplasty repair products and accessories; and a line of minimally invasive cardiac surgery tools for application in robotic heart valve surgery. In addition, ATS Medical is developing a patented technology, Particle Separation by Ultrasound, for auto-transfusion during cardiac surgery. The company markets and sells its products to hospitals in the United States, Canada, the United Kingdom, France, and Germany; and to independent distributors internationally. ATS Medical was founded in 1987 and is based in Minneapolis, Minnesota.


Float (mil) 37.60.......Shares Outstanding (mil) 49.21

Turnaround in the works.......
Improving fundamentals and nice chart pattern.
Got us a Double Bottom (reversal)Pattern @  $1.46

52wk Range: 1.46 - 2.80
Volume: 932,565
Avg Vol (3m): 83,228.7

Technicals
Close Above the 50-day MA
Percentage Gainer

Last Price Quote is:
25.92%above 13-day MA
17.67%above 50-day MA
RS Rating: 16 

Fundamentals
Key Data:
Market Cap (M): $75.78 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/08/2007
Last Analyst Rating: Mkt Perform

AP
ATS Medical Ups Outlook on Acquisition
Tuesday June 19, 7:10 pm ET 
ATS Medical Raises Full-Year Guidance on $28M Acquisition of CryoCath Business


MINNEAPOLIS (AP) -- ATS Medical Inc., which makes products used in cardiac surgery, said Tuesday it will acquire a division of CryoCath Technologies Inc. and has raised its full-year revenue outlook.
ATS Medical will acquire Canada-based CryoCath's surgical cryoablation business for about $28 million, which includes a group of products designed to use extreme cold to destroy diseased tissue.


The purchase price includes a $22 million payment and the transaction's close, $2 million after certain manufacturing goals are met, and up to $4 million in payments based on future sales of certain products.

As a result of the deal, ATS Medical said it is increasing its full-year 2007 revenue forecast to $49 million to $51 million, from a previously announced range of $46 million to $47 million. Analysts expect 2007 revenue of $46.4 million, according to a poll by Thomson Financial.

The company also said it expects 2008 revenue of $65 million to $70 million. Analysts polled by Thomson Financial estimate revenue of $57.5 million.

The transaction will allow the company to attain profitability in the second half of 2008, which is ahead of forecasts, the company said. Analysts expect the company to lose 34 cents a share in 2007 and 18 cents a share in 2008, according to Thomson Financial.

The acquisition is expected to close within 10 days, and will be financed with a $8.6 million senior secured term loan and a private placement of 9.8 million shares of common stock $1.65 per share to venture capital firm Alta Partners. Alta will also receive a warrant to purchase 1.96 million shares of ATS common stock at $1.65 per share.

When the deal closes, ATS will have about 59.1 million common shares outstanding.

Questions or comments about this story should be directed to AP Financial News at 212-621-7190.

Cup with Handle (continuation) Pattern
"The Golden Cross"
ATS Medical, Inc. engages in the development, manufacture, and marketing of medical devices for the treatment of structural heart disease.

52wk Range: 1.63 - 3.33
Volume: 222,279
Avg Vol (3m): 172,864

Technicals
Last Price Quote is:
1.23%above 13-day MA
6.92%above 50-day MA
RS Rating: 65 

Fundamentals
Key Data:
Market Cap (M): $200.76 
P/E Ratio: NA 
PEG Ratio: -5.80889 
Next Earnings: 08/10/2009
Last Analyst Rating: Outperform

MINNEAPOLIS, May 12, 2009 /PRNewswire-FirstCall via COMTEX/ -- ATS Medical, Inc. (ATSI, Trade), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced FDA clearance of the ATS Simulus(R) Adjustable Annuloplasty Band.

The ATS Simulus Adjustable Annuloplasty Band is the next product in a portfolio of mitral valve repair products developed and commercialized through the Company's partnership with Genesee BioMedical.

This band respects the natural motion of the mitral annulus and its proximity to the aortic valve allowing for a safe, physiologic valve repair. The simple but elegant design of the ATS Simulus Adjustable Band allows the surgeon to make asymmetric or symmetric adjustments to the posterior segment of the mitral valve annulus at any time during the procedure, optimizing the repair. This product is also indicated for tricuspid valve repair, where a band is the preferred annuloplasty device.

Annuloplasty rings and bands are used in those cases where repair of a patient's heart valve is preferable to replacement of the valve. The ATS Simulus Adjustable Band provides additional options for surgeons in terms of different exposures, double valve procedures and minimally invasive implants.

This Simulus Adjustable Band is another product developed as a result of the collaboration between ATS and Genesee Biomedical. John Wright, PhD, CEO of GBI has been involved in heart valves and valve repair therapy for more than 25 years. Dr Wright's depth of experience has contributed significantly to the enormous growth of the Simulus product line.

Michael Dale, President and CEO of ATS Medical commented: "Our valve repair business continues to grow and build momentum. We have expanded our repair platform by adding offerings in the flexible and semi-rigid segments. The breadth of our portfolio will enable more choices for our surgeon customers to accommodate their clinical needs and that of their patients, thus bolstering our growth prospects."

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.



http://www.atsmedical.com 

Copyright (C) 2009 PR Newswire. All rights reserved

updated chart look...

52wk Range: 1.63 - 3.58
Volume: 221,994
Avg Vol (3m): 544,032

Technicals
Last Price Quote is:
-5.69%below 13-day MA
-5.07%below 50-day MA
RS Rating: 43 

Fundamentals
Key Data:
Market Cap (M): $215.81 
P/E Ratio: NA 
PEG Ratio: -4.45778 
Next Earnings: 11/09/2009
Last Analyst Rating: Outperform